Som ved andre antipsykotika tilrådes relevant klinisk monitorering af diabetespatienter og patienter med risiko for udvikling af diabetes mellitus.
As with other antipsychotics, appropriate clinical monitoring is advisable in diabetic patients and in patients with risk factors for the development of diabetes mellitus.